性别确认激素治疗对跨性别成人的代谢影响

IF 0.5 Q4 ENDOCRINOLOGY & METABOLISM

Practical Diabetes Pub Date : 2023-01-01 DOI:10.1002/pdi.2453

Nadia Vloemans, M. Al-Mrayat

{"title":"性别确认激素治疗对跨性别成人的代谢影响","authors":"Nadia Vloemans, M. Al-Mrayat","doi":"10.1002/pdi.2453","DOIUrl":null,"url":null,"abstract":"As more individuals seek to align their physical characteristics with their gender identity, transgender health care is a growing medical field which is no longer the remit of a few selected clinicians. Gender‐affirming hormone therapy (GAHT) is a mainstay treatment in gender reassignment and its medium‐ to long‐term metabolic sequelae are gradually emerging. Although hampered by the scarcity of prospective controlled studies involving large diverse cohorts, evidence suggests a potential adverse impact for at least some cardiovascular disease (CVD) risk factors. If left unmanaged, this could manifest in a higher CVD events rate for this treatment group. Increased vigilance and awareness among health care professionals about the consequential risks of GAHT are important for proactive mitigation of this. Copyright © 2023 John Wiley & Sons.","PeriodicalId":20309,"journal":{"name":"Practical Diabetes","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic consequences of gender‐affirming hormone therapy in transgender adult persons\",\"authors\":\"Nadia Vloemans, M. Al-Mrayat\",\"doi\":\"10.1002/pdi.2453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As more individuals seek to align their physical characteristics with their gender identity, transgender health care is a growing medical field which is no longer the remit of a few selected clinicians. Gender‐affirming hormone therapy (GAHT) is a mainstay treatment in gender reassignment and its medium‐ to long‐term metabolic sequelae are gradually emerging. Although hampered by the scarcity of prospective controlled studies involving large diverse cohorts, evidence suggests a potential adverse impact for at least some cardiovascular disease (CVD) risk factors. If left unmanaged, this could manifest in a higher CVD events rate for this treatment group. Increased vigilance and awareness among health care professionals about the consequential risks of GAHT are important for proactive mitigation of this. Copyright © 2023 John Wiley & Sons.\",\"PeriodicalId\":20309,\"journal\":{\"name\":\"Practical Diabetes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Practical Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pdi.2453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Practical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pdi.2453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

随着越来越多的人寻求使他们的身体特征与他们的性别认同相一致，跨性别医疗保健是一个不断发展的医学领域，不再是少数选定的临床医生的职权范围。性别确认激素治疗(GAHT)是性别重置的主要治疗方法，其中长期代谢后遗症正在逐渐显现。尽管由于缺乏涉及大量不同队列的前瞻性对照研究，但有证据表明，至少对某些心血管疾病(CVD)危险因素有潜在的不利影响。如果不加以管理，这可能表现为该治疗组较高的CVD事件发生率。提高卫生保健专业人员对GAHT的相应风险的警惕性和认识对于主动减轻这种风险非常重要。版权所有©2023 John Wiley & Sons。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metabolic consequences of gender‐affirming hormone therapy in transgender adult persons

As more individuals seek to align their physical characteristics with their gender identity, transgender health care is a growing medical field which is no longer the remit of a few selected clinicians. Gender‐affirming hormone therapy (GAHT) is a mainstay treatment in gender reassignment and its medium‐ to long‐term metabolic sequelae are gradually emerging. Although hampered by the scarcity of prospective controlled studies involving large diverse cohorts, evidence suggests a potential adverse impact for at least some cardiovascular disease (CVD) risk factors. If left unmanaged, this could manifest in a higher CVD events rate for this treatment group. Increased vigilance and awareness among health care professionals about the consequential risks of GAHT are important for proactive mitigation of this. Copyright © 2023 John Wiley & Sons.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Practical Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

1.10

自引率

16.70%

发文量

期刊介绍： Practical Diabetes concerns itself with all aspects of the worldwide clinical science and practice of diabetes medicine. The journal recognises the importance of each member of the healthcare team in the delivery of diabetes care, and reflects this diversity of professional interest in its editorial contents. The Editors welcome original papers, case reports, practice points, audit articles and letters on any aspect of clinical diabetes care from any part of the world. The journal also publishes commissioned leaders, review articles and educational and training series, for which an honorarium normally is paid. All articles submitted to Practical Diabetes are independently peer reviewed. They must not have been published or be under submission currently elsewhere. Enquiries from prospective authors are welcomed and the Editors will be pleased, if asked, to advise on preparation and submission of articles. All articles and enquiries should be directed to the Editors at the publishing address below. The journal is published nine times a year, and currently the average waiting time for acceptance of articles is eight weeks, and for subsequent publication sixteen weeks. Practical Diabetes is independent of any commercial or vested interest.